Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a95c392ba1d5c38c76d57af3a7e57af |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-743 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6872 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 |
filingDate |
2005-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_154e8164f2e495f95b56f50b7e8f23ff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c124c551abbc3240f9b46966b7dc96c |
publicationDate |
2005-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
TW-200536549-A |
titleOfInvention |
Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof |
abstract |
The present invention includes novel methods and compositions for inhibiting or reducing steroid-dependent gene activation including the administration of at least two compounds that act different steps within a steroid receptor gene activation pathway. Preferred methods may include administering a first compound able to induce degradation of a steroid receptor and administering a second compound able to inhibit gene activation at a different step of the steroid receptor pathway. Steroid-dependent gene activation may be reduced or inhibited, modulated or controlled greater when the at least two of the compounds are administered in combination or together. |
priorityDate |
2004-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |